Voyager Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M |
| Research and development | $134.7M | $127.4M | $92.2M | $60.8M | $73.8M |
| Operating expenses | $172.2M | $163.3M | $128.0M | $91.7M | $111.0M |
| Operating income | -$131.8M | -$83.3M | $122.0M | -$50.8M | -$73.6M |
| Pretax income | -$119.6M | -$64.3M | $133.7M | -$46.4M | -$71.2M |
| Income tax expense | $144,000 | $665,000 | $1.4M | $16,000 | — |
| Net income | -$119.7M | -$65.0M | $132.3M | -$46.4M | -$71.2M |
| Balance Sheet | |||||
| Cash and equivalents | $65.3M | $71.4M | $68.8M | $99.0M | $117.4M |
| Current assets | $202.7M | $276.8M | $319.7M | $124.5M | $136.7M |
| Total assets | $252.3M | $393.1M | $351.3M | $159.4M | $193.9M |
| Current liabilities | $26.5M | $49.8M | $64.5M | $72.6M | $51.0M |
| Total liabilities | $56.2M | $93.3M | $115.0M | $100.3M | $98.8M |
| Stockholders' equity | $196.1M | $299.8M | $236.3M | $59.0M | $95.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$132.5M | -$15.3M | $77.9M | -$12.5M | -$53.5M |
| Depreciation and amortization | $4.1M | $4.7M | $4.4M | $6.2M | $5.2M |
| Stock-based compensation | $14.8M | $14.8M | $11.2M | $9.3M | $11.3M |
| Capital expenditure | $2.6M | $3.5M | $3.3M | $2.5M | $1.6M |
| Free cash flow | -$135.1M | -$18.8M | $74.7M | -$15.0M | -$55.1M |
Shares outstanding 60.4M · Free float 55.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.